Clinical relevance of genetic alterations in lung cancer

  • E. Jassem
  • J. Jassem
Chapter
Part of the MCBU Molecular and Cell Biology Updates book series (MCBU)

Abstract

Lung cancer is the most common human malignancy in the world and its incidence is increasing. Each year there are almost one million deaths due to lung cancer worldwide, accounting for 40% of all cancer deaths in men and 20% in women. Surgery remains the mainstay of lung cancer treatment. Detection of lung cancer, however, usually occurs late in the course of disease, and in most cases, by the time of presentation the tumour is not amenable to curative resection. Thus, the vast majority of patients are managed with radiation, chemotherapy or a combination of the two. Despite the continued refinement of radiotherapy techniques and progress in pharmacotherapy, in patients to whom these modalities are applied the 5-year survival rates are still only 5–10%.

Keywords

Lung Cancer Epidermal Growth Factor Receptor Small Cell Lung Cancer Microsatellite Instability Small Cell Lung Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ryberg D, Hewer A, Phillips DH, Haugen A (1994) Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res 54: 5801–5803.PubMedGoogle Scholar
  2. 2.
    Denissenko MF, Pao A, Tang M, Pfeifer GP (1996) Preferential formation of benzo(a)pyrene adducts at lung cancer mutational hot spots in p53. Science 274: 430–432.PubMedCrossRefGoogle Scholar
  3. 3.
    Yuspa SH, Pirier MC (1988) Chemical carcinogenesis: from animal models to molecular models in one decade. Adv Cancer Res 50: 25–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Tang MS, Pierce JR, Doisy RP, Nazimiec ME, MacLeod MC (1992) Differences and similarities in the repair of benzo[a]pyrene diol epoxide isomers induced DNA adducts by uvrA, uvrB, uvrC gene products. Biochemistry 32: 8429–8436.CrossRefGoogle Scholar
  5. 5.
    Chen RH, Maher VM, Brouwer J, van de Putte P, McCormick JJ (1992) Preferential repair and strand-specific repair of benzo[a]pyrene diol epoxide adducts in HPRT gene of diploid human fibroblasts. Proc Natl Acad Sci USA 89: 5413–5417.PubMedCrossRefGoogle Scholar
  6. 6.
    Seidegard J, Vorachek WR, Pero WR, Pearson WR (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci USA 85: 7293–7297.PubMedCrossRefGoogle Scholar
  7. 7.
    Spivack SD, Fasco MJ, Walker VE, Kaminsky LS (1997) The molecular epidemiology of lung cancer. Crit Rev Toxicol 27: 319–365.PubMedCrossRefGoogle Scholar
  8. 8.
    Hayashi S-I, Watanabe J, Kawajiri K (1992) High susceptibility to lung cancer analyzed in terms of combined genotypes of P450Ial and Mu-class glutathione S-transferase genes. Jpn J Cancer Res 83: 866–870.PubMedCrossRefGoogle Scholar
  9. 9.
    Goto I, Yoneda S, Yamamoto M, Kawajiri K (1996) Prognostic significance of germ line polymorphism of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. Cancer Res 56: 3725–3730.PubMedGoogle Scholar
  10. 10.
    Todd S, Franklin WA, Varella-Garcia M, Kennedy T, Hilliker CE, Hahner L, Anderson M, Wiest JS, Drabkin HA, Gemmill RM (1997) Homozygous deletions of human chromosome 3p in lung tumors. Cancer Res 57: 1344–1352.PubMedGoogle Scholar
  11. 11.
    Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, Degregorio L, Pastorino U et al. (1996) The FHIT gene 3pl4.2 is abnormal in lung cancer. Cell 85: 17–26.PubMedCrossRefGoogle Scholar
  12. 12.
    Fong KM, Biesterveld EJ, Virmani A, Wistuba I, Sekido Y, Bader SA, Ahmadian M, Ong ST, Rassool FV, Zimmerman PV et al. (1997) FHIT and FRA3B 3pl4.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res 57: 2256–2267.PubMedGoogle Scholar
  13. 13.
    Gayther SA, Barski P, Batley SJ, Li L de Foy KAF, Cohen SN, Ponder BAJ, Caldas C (1997) Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissue and mimics alterations previously described in tumours. Oncogene 15: 2119–2127.PubMedCrossRefGoogle Scholar
  14. 14.
    Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehan NM, Rabbits P (1992) p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Oncogene 7: 1989–1897.PubMedGoogle Scholar
  15. 15.
    Ridanpää M, Anttila S, Husgafvel-Pursiainen K (1995) Detection of loss of heterozygosity in the p53 tumor suppressor gene using a PCR-based assay. Pathol Res Pract 191: 399–402.PubMedCrossRefGoogle Scholar
  16. 16.
    Takeuchi S, Mori N, Koike M, Slater J, Park S, Miller CW, Miyoshi I, Koeffler HP (1996) Frequent loss of heterozygosity in region of the KIP1 locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. Cancer Res 56: 738–740.PubMedGoogle Scholar
  17. 17.
    Fong KM, Kida Y, Zimmerman PV, Ikenaga M, Smith PJ (1995) Loss of heterozygosity frequently affects chromosome 17q in non-small cell lung cancer. Cancer Res 55: 4268–4272.PubMedGoogle Scholar
  18. 18.
    Miura I, Graziano SL, Cheng JQ, Doyle LA, Testa JR (1992) Chromosome alterations in human small cell lung cancer: frequent involvement of 5q. Cancer Res 52: 1322–1328.PubMedGoogle Scholar
  19. 19.
    Fong K, Zimmerman PV, Smith P (1995) Tumor progression and loss of heterozygosity at 5q and 18q in non-small cell lung cancer. Cancer Res 55: 220–223.PubMedGoogle Scholar
  20. 20.
    Tran YK, Newsham IF (1996) High-density marker analysis of 11pl5.5 in non-small cell lung carcinomas reveals allelic deletion of one shared and one distinct region when compared to breast carcinomas. Cancer Res 56: 2916–2921.PubMedGoogle Scholar
  21. 21.
    Rasio D, Negrini M, Maneneti G, Draggani TA, Croce CM (1995) Loss of heterozygosity at chromosome 1 lq in lung adenocarcinoma: identification of three independent regions. Cancer Res 55: 3988–3991.PubMedGoogle Scholar
  22. 22.
    Uchida K, Nagatake M, Osada H, Yatabe Y, Kondo M, Mitsudomi T, Masuda A, Takahashi T, Takahashi T (1997) Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res 57: 5583–5585.Google Scholar
  23. 23.
    Balsara BR, Sonoda G, du Manoir S, Siegfried JM, Gabrielson E, Testa JR (1997) Comparative genomic hybridization analysis detects frequent, often high-level overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung cancer. Cancer Res 57: 2116–2120.PubMedGoogle Scholar
  24. 24.
    Brass N, Ukena I, Remberger K, Mack U, Sybrecht GW, Meese EU (1996) DNA amplification on chromosome 3q26.1-q26.3 in squamous cell carcinoma of the lung detected by reverse chromosome painting. EurJ Cancer 32A: 1205–1208.CrossRefGoogle Scholar
  25. 25.
    Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 gene in human cancers. Nature Med 1: 686–692.PubMedCrossRefGoogle Scholar
  26. 26.
    Nagatake M, Osada H, Kondo M, Uchida K, Mishio M, Shimokata K, Takahashi T, Takahashi T (1996) Aberrant hypermethylation at the bcl-2 locus at 18q21 in human lung cancers. Cancer Res 56: 1886–1891.PubMedGoogle Scholar
  27. 27.
    Hearne CM, Ghosh S, Todd JA (1992) Microsatellites for linkage analysis of genetic traits. Trends Genet 8: 288–294.PubMedGoogle Scholar
  28. 28.
    Modrich P, Lahue R (1996) Mismatch repair in replication fidelity, genetic recombination and cancer biology. Anna Rev Biochem 65: 101–133.CrossRefGoogle Scholar
  29. 29.
    Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R (1993) The human imitator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027–1038.PubMedCrossRefGoogle Scholar
  30. 30.
    Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A et al. (1994) Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 368: 258–261.PubMedCrossRefGoogle Scholar
  31. 31.
    Risinger JI, Umar A, Barrett JC, Kunkel TA (1995) A hPMS2 mutant cell line is defective in strand-specific mismatch repair. J Biol Chem 270: 18183–18186.PubMedCrossRefGoogle Scholar
  32. 32.
    Pifarre A, Rosell R, Monzo M, De Anta JM, Moreno I, Sanchez JJ, Ariza A, Mate JL, Martinez E, Sanchez M (1997) Prognostic value of replication errors on chromosomes 2p and 3p in non-small cell lung cancer. Brit J Cancer 75: 184–189.PubMedCrossRefGoogle Scholar
  33. 33.
    Chen XQ, Stroun M, Magnenat J-L, Nicod JL, Lederrey C, Anker P (1996) Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Med 2: 1033–1035.PubMedCrossRefGoogle Scholar
  34. 34.
    Merlo A, Mabry M, Gabrielson E, Vollmer R, Baylin SB, Sidransky D (1994) Frequent microsatellite instability in primary small cell lung cancer. Cancer Res 54: 2098–2101.PubMedGoogle Scholar
  35. 35.
    Shridhar V, Siegfried J, Hunt J, Alonso MDM, Smith DI (1994) Genetic instability of microsatellite sequences in many non-small cell lung carcinomas. Cancer Res 54: 2084–2087.PubMedGoogle Scholar
  36. 36.
    Counter CM, Avilion AA, LeFeuvre CE (1992) Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 11: 1921–1929.PubMedGoogle Scholar
  37. 37.
    Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Wienrich SL, Shay J (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011–2015.PubMedCrossRefGoogle Scholar
  38. 38.
    Zakian VA (1995) Telomeres: beginning to understand the end. Science 270: 1601–1607.PubMedCrossRefGoogle Scholar
  39. 39.
    Shay JW, Werbin H, Wright WE (1994) Telomere shortening may contribute to aging and cancer. Mol Cell Differ 2: 1–21.Google Scholar
  40. 40.
    Shirotani Y, Hiyama K, Ishioka S (1994) Alterations in length of telomeric repeats in lung cancer. Lung Cancer 11: 29–41.PubMedCrossRefGoogle Scholar
  41. 41.
    Shay JW, Gazdar AF (1997) Telomerase in the early detection of cancer. J Clin Pathol 50: 106–109.PubMedCrossRefGoogle Scholar
  42. 42.
    Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Witsuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW et al. (1997) Telomerase expression in respiratory epithelium during multistage pathogenesis of lung carcinomas. Cancer Res 57: 2373–2377.PubMedGoogle Scholar
  43. 43.
    Hiyama K, Ishioka S, Shirotani Y, Inai K, Hiyama E, Murakami I, Isobe T, Inamizu T, Yamakido M (1995) Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb. Oncogene 10: 937–944.PubMedGoogle Scholar
  44. 44.
    Rosell R, Monzo M, Molina F, Martinez E, Piffare A, Moreno I, Mate JL, de Anta JM, Sanchez M, Font A (1995) K-ras genotypes and prognosis in non-small cell lung cancer. Ann Oncol 6 (Suppl. 3): 15–20.Google Scholar
  45. 45.
    Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL (1987) Mutational activation of the K-ras oncogene: a possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317: 929–935.PubMedCrossRefGoogle Scholar
  46. 46.
    Mitsudomi T, Steinberg SM, Oie H, Mulshine JL, Phelps R, Viallet J, Pass H, Minna JD, Gazdar AF (1991) ras gene mutation in non-small cell lung cancers are associated with shortened survival irrespective of treatment. Cancer Res 51: 4999–5002.PubMedGoogle Scholar
  47. 47.
    Rodenhuis S (1992) ras in human tumors. Semin Cancer Biol 3: 241–247.PubMedGoogle Scholar
  48. 48.
    Slebos RJC, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJA, Rodenhuis S (1991) Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the lung. J Nat Cancer Inst 83: 1024–1027.PubMedCrossRefGoogle Scholar
  49. 49.
    Amati B, Land H (1994) Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev 4: 102–108.PubMedCrossRefGoogle Scholar
  50. 50.
    Harrington EA, Fanidi A, Evan GI (1994) Oncogenes and cell death. Curr Opin Genet Dev 4: 120–129.PubMedCrossRefGoogle Scholar
  51. 51.
    Brooks B, Battey J, Nau M, Gazdar A, Minna J (1987) Amplification and expression of the myc gene in small-cell lung cancer. Adv. Viral Oncol 7: 155–172.Google Scholar
  52. 52.
    Sherwin SA, Minna JD, Gazdar AF Todaro GJ (1981) Expression of epidermal growth factor and nerve growth factor receptors and soft agar growth factor production by lung cancer cells. Cancer Res 41: 3538–3542.PubMedGoogle Scholar
  53. 53.
    Cerny T, Barnes D, Haselton PS, Barber PV, Healy K, Gullick W, Thatcher N (1986) Expression of epidermal growth factor receptors in human lung tumors. Brit J Cancer 54: 265–269.PubMedCrossRefGoogle Scholar
  54. 54.
    Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K (1990) Immunohistochemical evidence of autocrine growth factors in adenocarcinoma of the human lung. Cancer Res 50: 7077–7080.PubMedGoogle Scholar
  55. 55.
    Jacobson MD, Burna JF, King MP, Miyashita T, Reed JC, Raff MC (1993) Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. Nature 361: 365–369.PubMedCrossRefGoogle Scholar
  56. 56.
    Pezella F, Turley H, Kuzu I, Tungekar MF, Dunnill MS, Pierce CB, Harris A, Gatter KC, Mason DY (1993) bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 329: 690–694.CrossRefGoogle Scholar
  57. 57.
    Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R (1995) High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anti-Cancer Res 15: 503–505.Google Scholar
  58. 58.
    Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer ethiology and molecular pathogenesis. Cancer Res 54: 4855–4878.PubMedGoogle Scholar
  59. 59.
    Chen X, Farmer G, Zhu H, Prywes R, Prives C (1993) Cooperative DNA binding of p53 with TFDD (TBP): a possible mechanism for transcriptional activation. Genes Dev 7: 1837–1849.PubMedCrossRefGoogle Scholar
  60. 60.
    el-Deiry WS, Harper JW, O’Connor PM, Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrel M, Hill DE, Wang Y et al. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169–1174.PubMedGoogle Scholar
  61. 61.
    Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81: 323–330.PubMedCrossRefGoogle Scholar
  62. 62.
    de Vos S, Miller CW, Takeuchi S, Gombart AF, Cho SK, Koeffler HP (1995) Alterations of CDKN2 (pl6) in non-small cell lung cancer. Gene Chromosome Cancer 14: 164–170.CrossRefGoogle Scholar
  63. 63.
    Moregenbesser SD, Williams BO, Jacks T (1994) p53 dependent apoptosis produced by Rb deficiency in developing mouse lens. Nature 371: 12–74.CrossRefGoogle Scholar
  64. 64.
    Bennett WP, Colby TV, Travis WD, Borkowski A, Jones RT, Lane DP, Metclaf RA, Samet JM, Takeshima Y, Gu JR et al. (1993) p53 protein accumulates frequently in early bronchial neoplasia. Cancer Res 53: 4817–4822.PubMedGoogle Scholar
  65. 65.
    Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen NM, Rabbitts P (1992) p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Oncogene 7: 1989–1997.PubMedGoogle Scholar
  66. 66.
    Thiberville L, Payne P, Vielkinds J, LeRiche J, Horsman D, Nouvet G, Palcic B, Lam S (1995) Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 55: 5133–5139.PubMedGoogle Scholar
  67. 67.
    Witsuba II, Lam S, Behrens C, Virmani AK, Fong KM, LeRiche J, Samet M, Srivastava S, Minna JD, Gazdar AF (1997) Molecular damage in the bronchial epithelium of current and former smokers. J Nat Cancer Inst 89: 1366–1373.CrossRefGoogle Scholar
  68. 68.
    Mao L, Lee JS, Kurie JM, Hong Y, Lippman SM, Lee JJ, Ro JY, Broxson A, Yu R, Morice RC et al. (1997) Clonal genetic alterations in the lungs of current and former smokers. J Nat Cancer Inst 89: 857–862.PubMedCrossRefGoogle Scholar
  69. 69.
    Sozzi G, Sard L, De Gregorio L, Marchetti A, Musso K, Buttitta F, Tornielli S, Pellegrini S, Veronese ML, Manenti G et al. (1997) Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57: 2121–2123.PubMedGoogle Scholar
  70. 70.
    Mao L, Hruban RH, Boyle JO, Tockman M, Sidransky D (1994) Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 54: 1634–1637.PubMedGoogle Scholar
  71. 71.
    Vahakangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP (1992) Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339: 576–80.PubMedCrossRefGoogle Scholar
  72. 72.
    Miozzo M, Sozzi G, Musso K, Pilotti S, Incarbone M, Pastorino U, Pierotti MA (1996) Microsatellite alterations in bronchial and sputum specimens of lung patients. Cancer Res 56: 2285–2288.PubMedGoogle Scholar
  73. 73.
    Mills NE, Fishman CL, Scholes J (1995) Detection of K-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J Nat Cancer Inst 87: 1056–1060.PubMedCrossRefGoogle Scholar
  74. 74.
    Lam S, MacAulay C, Palcic B (1993) Detection and localization of early lung cancer by imaging techniques. Chest 103: 12–14.CrossRefGoogle Scholar
  75. 75.
    Lubin R, Zalcman G, Bouchet L (1995) Serum p53 antibodies as early markers of lung cancer. Nature Med 1: 701–702.PubMedCrossRefGoogle Scholar
  76. 76.
    Jassem E, Bigda J, Jassem J, Rzyman W, Skokowski J, Grodzki T, Stominski JM (1997) Serum p53 auto-antibodies in small cell lung cancer. Eur Respir J 10 (Suppl. 25): 263, A1705 (abstract).Google Scholar
  77. 77.
    Slebos RJC, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJLM, Wagenaar SS, Vanderschueren RGJRA, van Zandwijk N, Mooi WJ et al. (1990) K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 323: 561–565.PubMedCrossRefGoogle Scholar
  78. 78.
    Rodenhuis S, Slebos RJC (1992) Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 52 (Suppl. 1): 2665s–2669s.PubMedGoogle Scholar
  79. 79.
    Harada M, Dosaka-Akita H, Miyamoto H, Kuzumaki N, Kawakami Y (1992) Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 69: 72–77.PubMedCrossRefGoogle Scholar
  80. 80.
    Keohavong P, De Michele MAA, Melacrinos AC, Landreneau RJ, Weyant RJ, Sigfried JM (1996) Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 2: 411–418.PubMedGoogle Scholar
  81. 81.
    Cho JY, Kim JH, Lee YH, Chung KY, Kim SK, Gong SJ, You NC, Chung HC, Roh JK, Kim BS (1997) Correlation between K-ras gene mutation and prognosis of patients with non-small cell lung carcinoma. Cancer 79: 462–467.PubMedCrossRefGoogle Scholar
  82. 82.
    Sugio K, Ishida T, Yokoyama H, Inone T, Sugimachi K, Sazazuki T (1992) ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 52: 2903–2906.PubMedGoogle Scholar
  83. 83.
    Rodenhuis S, Boerrigter L, Top B, Slebos RJC, Mooi WJ, van’t Veer L, Zandwijk N (1997) Mutational activation of K-ras oncogene and the effect of chemotherapy in advanced adenocarcinoma of the lung: a prospective study. J Clin Oncol 15: 285–291.PubMedGoogle Scholar
  84. 84.
    Keohavong P, Zhu D, Melacrinos AC, De Michele MA, Weyant RJ, Luketich JD, Testa JR, Fedder M, Siegfried JM (1997) Detection of low-fraction K-ras mutations in primary lung tumors using a sensitive method. Int J Cancer 74: 162–170.PubMedCrossRefGoogle Scholar
  85. 85.
    Tateishi M, Ishida T, Mitsudomi T, Kaneko S, Sugimachi K (1991) Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. Eur J Cancer 27: 1372–1375.PubMedCrossRefGoogle Scholar
  86. 86.
    Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, Weiner D, Schwartz DA (1994) C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 93: 516–520.PubMedCrossRefGoogle Scholar
  87. 87.
    Volm M, Drings P, Wodrich W (1993) Prognostic significance of the expression of c-fos, c-jun and c-erbB-2 oncogene products in human squamous cell carcinomas. J Cancer Res Clin Oncol 119: 507–510.PubMedCrossRefGoogle Scholar
  88. 88.
    Harpole DH, Herndon JE, Wolfe WG, Iglehart JD, Marks JR (1995) A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 55: 51–56.PubMedGoogle Scholar
  89. 89.
    Scagliotti GV, Leonardo E, Cappia S, Masiero P, Micela M, Gubetta L, Pozzi E (1993) Epidermal growth factor receptor and neu-oncogene expression in lung cancer. Proc Am Soc Clin Oncol 12: 328 (abstract).Google Scholar
  90. 90.
    Mitsudomi T, Oyama T, Nishida K, Ogami A, Osaki T, Nakanishi R, Surgio K, Yasumoto K, Sugimachi K (1995) p53 nuclear immunostaining and gene mutations in non-small cell lung cancer and their effect on patients survival. Ann Oncol 6 (Suppl. 3):S9–S13.PubMedGoogle Scholar
  91. 91.
    Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T, Shimokata K, Yamakawa K, Nakamura Y, Ueda R (1993) Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53: 1–4.PubMedGoogle Scholar
  92. 92.
    Chiba I, Takahashi T, Nau MM, D’Amico D, Curiel DT, Mitsudomi T, Buchhagen DL, Carbone D, Piantadosi S, Koga H et al. (1990) Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene 5: 1603–1610.PubMedGoogle Scholar
  93. 93.
    Carbone DP, Mitsudomi T, Chiba I, Piantadosi S, Rusch V, Nowak JA, Mclntire D, Slamon D, Gazdar A, Minna J (1994) p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. Chest 106: 377–381.CrossRefGoogle Scholar
  94. 94.
    Nishio M, Koshikawa T, Kuroishi T, Suyama M, Uchida K, Takagi Y, Washimi O, Sugiura T, Ariyoshi Y, Takahashi T et al. (1996) Prognostic significance of abnormal p53 accumulation in primary, resected non-small cell lung cancers. J Clin Oncol 14: 497–502.PubMedGoogle Scholar
  95. 95.
    McLaren R, Kuzu I, Dunnill M, Harris A, Lane D, Gatter KC (1992) The relationship of p53 immunostaining to survival in carcinoma of the lung. Brit J Cancer 66: 735–738.PubMedCrossRefGoogle Scholar
  96. 96.
    Passlick B, Izbicki JR, Haussinger K, Thettero O, Pantel K (1995) Immunohistochemical detection of p53 protein is not associated with a poor prognosis in non-small-cell lung cancer. J Thorac Cardiovasc Surg 109: 1205–1211.PubMedCrossRefGoogle Scholar
  97. 97.
    Rosenfeld MR, Malats N, Schramm L, Vinolas N, Rosell R, Tora M, Real FX, Posner JB, Dalmau J (1997) Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Nat Cancer Inst 89: 381–385.PubMedCrossRefGoogle Scholar
  98. 98.
    de Anta JM, Jassem E, Rosell R, Martinez-Roca M, Jassem J, Martinez-Lopez E, Monzo M, Sanchez-Hernandez JJ, Moreno I, Sanchez-Cespedes M (1997) TPp53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis. Oncogene 24: 2951–2959.CrossRefGoogle Scholar
  99. 99.
    Chiba W, Sawai S, Hanawa T, Ishida H, Matsui T, Kosaba S, Watanabe S, Hatakenaka R, Matsubara Y, Funatsu T et al. (1993) Correlation between DNA content and amplification of oncogenes (c-myc, L-myc, c-erB-2) and correlation with prognosis in 143 cases of resected lung cancer. Gan Ro Kagaku Ryoho 20: 824–827.Google Scholar
  100. 100.
    Kawashima K, Nomura S, Hirai H, Fukushi S, Karube T, Takeushi K, Naruke T, Nishimura S (1992) Correlation of L-myc RFLP with metastasis, prognosis and multiple cancer in lung-cancer patients. Int J Cancer 50: 557–561.PubMedCrossRefGoogle Scholar
  101. 101.
    Fong KM, Kida Y, Zimmerman PV, Smith PJ (1996) MYCL genotypes and loss of heterozygosity in non-small cell lung cancer. Brit J Cancer 74: 1975–1978.PubMedCrossRefGoogle Scholar
  102. 102.
    Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, Geradts J (1996) Rb and p16 INK4a expression in resected non-small cell lung tumors. Cancer Res 56: 3415–3420.PubMedGoogle Scholar
  103. 103.
    Pastorino U, Andreola S, Tagliabue E, Pezzella F, Incarbone M, Sozzi G, Buyse M, Menard S, Pierotti M, Rilke F (1997) Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 15: 2858–2866.PubMedGoogle Scholar
  104. 104.
    Dosaka-Akita H, Hu S-X, Fujino M, Harada M, Kinoshita I, Xu H-J, Kuzumaki N, Kawakami Y, Benedict WF (1997) Altered retinoblastoma protein expression in non-small cell lung cancer. Cancer 79: 1329–1337.PubMedCrossRefGoogle Scholar
  105. 105.
    Fontanini G, Vignati S, Bigini D, Mussi A, Lucchi M, Angeletti CA, Basolo F, Bevilacqua G (1995) Bcl-2 protein: a prognostic factor inversely correlated to p-53 in non-small-cell lung cancer. Brit J Cancer 71: 1003–1007.PubMedCrossRefGoogle Scholar
  106. 106.
    Ritter JH, Dresler CM, Wick MR (1995) Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma. Hum Pathol 26: 1227–1232.PubMedCrossRefGoogle Scholar
  107. 107.
    Lane DP (1993) A death in the life of p53. Nature 362: 786–787.PubMedCrossRefGoogle Scholar
  108. 108.
    Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993) p53 is required for radiation induced apoptosis in mouse thymocytes. Nature 362: 847–849.PubMedCrossRefGoogle Scholar
  109. 109.
    Rosell R, Gonzalez-Larriba JS, Alberola V, Molina F, Monzo M, Benito D, Perez JM, de Anta JM (1995) Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: Links between p53 and K-ras gene status and chemosensitivity. Sem Oncol 22 (Suppl. 14): 12–18.Google Scholar
  110. 110.
    Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E (1995) Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55: 5038–5042.PubMedGoogle Scholar
  111. 111.
    Tsai CM, Chang KT, Perng RP, Mitsudomi T, Chen MH, Kadoyama C, Gazdar AF (1993) Correlation of intrinsic chemoresistance of non-small cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Nat Cancer Inst 85: 897–901.PubMedCrossRefGoogle Scholar
  112. 112.
    Funa K, Steinholz L, Nou M, Bergh J (1987) Amplification and expression of N-myc in human small cell lung cancer biopsies predict lack of response to chemotherapy and poor prognosis. Am. J Clin Pathol 88: 216–220.PubMedGoogle Scholar
  113. 113.
    Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881–4886.PubMedGoogle Scholar
  114. 114.
    Langendijk JA, Thunnissen FBJM, Lamers RJS, de Jong JMA, ten Velde GPM, Wouters EFM (1995) The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother Oncol 36: 218–224.PubMedCrossRefGoogle Scholar
  115. 115.
    Pastorino U (1995) Lung cancer chemoprevention. Cancer Treat Res 72: 43–74.PubMedCrossRefGoogle Scholar
  116. 116.
    Stribling R, Brunette E, Liggitt D, Gaensler K, Debs R (1992) Aerosol gene delivery in vivo. Proc Natl Acad Sci USA 89: 11277–11281.PubMedCrossRefGoogle Scholar
  117. 117.
    Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC et al. (1996) Retrovirus-mediated wildtype p53 gene transfer to tumors of patients with lung cancer. Nature Med 2: 985–991.PubMedCrossRefGoogle Scholar
  118. 118.
    Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA (1994) Therapeutic effect of a retroviral wildtype p53 expression vector in an orthotopic lung cancer model. J Nat Cancer Inst 86: 1458–1462.PubMedCrossRefGoogle Scholar
  119. 119.
    Roth JA, Cristiano RJ (1997) Gene therapy for cancer: what have we done and where are we going? J Nat Cancer Inst 89: 21–39.PubMedCrossRefGoogle Scholar
  120. 120.
    Tursz T, Cesne AL, Baldeyrou P, Gautier E, Opolon P, Schartz C, Pavirani A, Courtney M, Lamy D, Ragot T et al. (1996) Phase I study of a recombinant adenovirus-mediated gene transfer in lung cancer patients. J Nat Cancer Inst 88: 1857–1863.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Basel AG 1998

Authors and Affiliations

  • E. Jassem
    • 1
  • J. Jassem
    • 2
  1. 1.Department of PneumonologyMedical University of GdanskGdanskPoland
  2. 2.Department of Oncology and RadiotherapyMedical University of GdanskGdanskPoland

Personalised recommendations